



Supplementary Table 1 Baseline characteristics of the included and excluded patients

	Included patients N = 1805	Excluded patients N = 1155	<i>p</i> value
Age at diagnosis, years			0.542
Median (range)	57 (18–86)	57 (18–82)	
Sex			0.229
Male	1121 (62.1)	691 (59.8)	
Female	684 (37.9)	464 (40.2)	
BMI (kg/m ²)			
Median (IQR)	22.8 (20.8–25.0)	22.8 (20.7–24.9)	0.770
Normal (18.5–24.9)	1233 (68.3)	289 (69.5)	0.899
Obese (≥ 25.0)	447 (24.8)	99 (23.8)	
Underweight (< 18.5)	125 (6.9)	28 (6.7)	
Disease status			< 0.001
Recurrent	551 (30.5)	484 (41.9)	
Initially metastatic	1254 (69.5)	671 (58.1)	
Primary site			0.250
Right colon	407 (22.6)	282 (24.4)	
Left colon	676 (37.5)	391 (33.9)	
Rectum	698 (38.7)	466 (40.3)	
Multifocal/unknown	24 (1.3)	16 (1.4)	
MSI/MMR status			0.016
MSS/pMMR	1203 (66.6)	739 (64.0)	
MSI–H/dMMR	57 (3.2)	60 (5.2)	
Unknown	545 (30.2)	356 (30.8)	
Palliative first-line regimen			0.449
Bevacizumab-containing	433 (24.0)	262 (22.7)	
Cetuximab-containing	130 (7.2)	74 (6.4)	
Chemotherapy only	1242 (68.8)	819 (70.9)	
Metastasectomy	249 (13.8)	124 (10.7)	0.017





Supplementary Figure 1 Age at diagnosis and body composition. (A) Sarcopenia T-score, (B) Myosteatosis T-score, (C) Visceral fat area, (D) Subcutaneous fat area index, (E) BMI.

A



B





Supplementary Figure 2 Sensitivity survival analyses for determining cut-offs for significant changes in body composition parameters from baseline to after stopping palliative chemotherapy. (A) Sarcopenia T-score, (B) Myosteatosis T-score, (C) Visceral fat area, (D) Subcutaneous fat area index. Abbreviations: SFAI, subcutaneous fat area index; VFA, visceral fat area.